Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure

Petar M. Seferović*, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D. Anker, Robin Ray, Yuksel Çavuşoğlu, Marija Polovina, Marco Metra, Giuseppe Ambrosio, Krishna Prasad, Jelena Seferović, Pardeep S. Jhund, Giuseppe Dattilo, Jelena Čelutkiene, Massimo Piepoli, Brenda MouraOvidiu Chioncel, Tuvia Ben Gal, Stephane Heymans, Tiny Jaarsma, Loreena Hill, Yuri Lopatin, Alexander R. Lyon, Piotr Ponikowski, Mitja Lainščak, Ewa Jankowska, Christian Mueller, Francesco Cosentino, Lars H. Lund, Gerasimos S. Filippatos, Frank Ruschitzka, Andrew J.S. Coats, Giuseppe M.C. Rosano

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:. • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.

Original languageEnglish
Pages (from-to)1984-1986
Number of pages3
JournalEuropean Journal of Heart Failure
Volume22
Issue number11
Early online date27 Oct 2020
DOIs
Publication statusPublished - 29 Nov 2020

Bibliographical note

Funding Information:
P.M.S. reports honorarium for lecture from Medtronic, Abbott, Servier, AstraZeneca, Respicardia; consultancy agreement and honorarium for lecture from Boehringer Ingelheim, Novartis; and consultancy agreement from Vifor Pharma. M.P. reports grants and personal fees from AstraZeneca, Novartis, Novo Nordisk, Boehringer Ingelheim, Abbvie, Takeda, Bayer, Pharmacosmos; personal fees from Vifor, Cardiorentis, Alnylam, outside the submitted work. R.F. reports personal fees from Servier International, Merck Serono, Pfizer, DOC Generici, Società Prodotti Antibiotici Spa; grants and personal fees from Novartis, outside the submitted work. T.T. reports personal fees and other from Cardior Pharmaceuticals GmbH, outside the submitted work. J.B. reports personal fees from Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, MSD, Novartis, Pfizer, Servier; grants and personal fees from Abiomed, CvRX, Vifor, Zoll, outside the submitted work. M.P. reports honorarium for lecture from Boehringer Ingelheim, outside the submitted work. M.M. reports personal fees from minimal amount honoraria from AstraZeneca, Abbott Vascular, Bayer, Edwards Therapeutics, Vifor Pharma for participation in trials' committees or public speeches, outside the submitted work. J.Č. reports personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, Servier, Amgen, outside the submitted work. L.H. reports personal fees from Novartis, outside the submitted work. A.R.L. reports personal fees from Ferring Pharmaceuticals, Eli Lily, Bristol Myers Squibb, Eisai Ltd, Myocardial Solutions and Heartfelt Technologies. C.M. reports personal fees from AstraZeneca, Boehringer Ingelheim, outside the submitted work. L.H.L. reports personal fees from Merck, Sanofi, Bayer, Pharmacosmos, Abbott, Medscape, Myokardia; grants and personal fees from Vifor‐Fresenius, AstraZeneca, Relypsa, Novartis, Mundipharma, Boehringer Ingelheim; grants from Boston Scientific, outside the submitted work. G.S.F. reports other from Committee Member in trials sponsored by Medtronic, Vifor, Servier, Novartis, BI, outside the submitted work. F.R. since 1 January 2018: no personal payments; all payments directly to the University of Zurich; before 2018: reports grants and personal fees from SJM/Abbott, Servier, Novartis, Bayer; personal fees from Zoll, AstraZeneca, Sanofi, Amgen, BMS, Pfizer, Fresenius, Vifor, Roche, Cardiorentis, Boehringer Ingelheim; other from Heartware, grants from Mars, outside the submitted work. F.C. reports personal fees from Novo Nordisk, MSD, Pfizer, Mundipharma, Lilly, AstraZeneca, BMS, outside the submitted work. A.J.S.C. reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, Novartis, Nutricia, Servier, Vifor, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Gore, Impulse Dynamics, Respicardia, outside the submitted work, S.D.A. reports grants and personal fees from Vifor Int, Abbott Vascular; personal fees from Bayer, Boehringer Ingelheim, Novartis, Servier, Impulse Dynamics, Cardiac Dimensions, outside the submitted work. P.P. reports personal fees and other from Boehringer Ingelheim, AstraZeneca, during the conduct of the study; personal fees and other from Amgen, Novartis, Servier, Bayer, BMS, Vifor Pharma, Renal Guard Solutions, Impulse Dynamics, personal fees from Pfizer, Berlin Chemie, outside the submitted work. B.M. reports personal fees from Boehringer Ingelheim, AstraZeneca, outside the submitted work. M.L. reports personal fees from AstraZeneca, Boehringer Ingelheim, during the conduct of the study. All other authors have noting to disclose. Conflict of interest:

Publisher Copyright:
© 2020 European Society of Cardiology

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

  • Cardiovascular outcomes
  • Heart failure
  • Renal function
  • Sodium–glucose co-transporter 2 inhibitors
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure'. Together they form a unique fingerprint.

Cite this